The Science, In Depth
Mild vs. High Pressure HBOT: Understanding the Evidence
A significant debate exists within the hyperbaric medicine community about the optimal atmospheric pressure for treatment — with particular controversy over whether 1.3 ATA (atmospheres absolute) represents an inert placebo or an active therapeutic intervention.
The core disagreement
The controversy centers on study design and what counts as a "sham" treatment. Historically, many researchers used 1.2–1.3 ATA with room air (21% oxygen) as a control condition in clinical trials, assuming that pressures below 1.4 ATA with air would be therapeutically inert. That assumption is increasingly challenged by evidence that even mild hyperbaric pressures produce real biological effects.
The problem with "sham" controls
When studies use 1.3 ATA as the baseline or sham condition and report inconclusive results, some researchers argue this may be because both groups are actually receiving active treatment. Breathing regular air at 1.3 ATA is roughly equivalent to breathing 27–28% oxygen at normal atmospheric pressure — a more than 50% elevation in tissue oxygenation. This creates a fundamental problem: the "placebo" group may be experiencing genuine therapeutic benefit, masking the true effectiveness of higher-pressure protocols.
Multiple editorials published in Undersea and Hyperbaric Medicine have strongly objected to using hyperbaric pressurization as a valid control condition, since it is not truly an inert intervention. Even slight increases in the partial pressure of oxygen — or pressure alone — can cause measurable physiological changes.
Evidence supporting lower-pressure efficacy
Several clinical studies support the therapeutic potential of lower pressures. A 2024 systematic review of PTSD treatment found reliable improvement at pressures as low as 1.3 ATA, with a minimum threshold for symptom improvement appearing around 1.2–1.3 ATA. In the Wolf et al. study, subjects receiving 1.3 ATA with ordinary 21% oxygen experienced a statistically significant 8.3-point reduction in PTSD symptoms — nearly identical to the 8.4-point reduction seen in a group treated at 2.4 ATA with 100% oxygen.
Similarly, the Miller et al. study found an 11.4-point decrease in symptoms with 1.2 ATA treatment, compared with only a 5.0-point decrease in a group treated at 1.5 ATA with 100% oxygen. And a 2021 validation study confirmed that compression to 1.3 ATA, combined with proper blinding, successfully simulates therapeutic compression and can be perceived by patients as full treatment pressure.
The case for mild hyperbaric therapy
Advocates for lower-pressure protocols point to three key advantages:
Safety. Lower pressures significantly reduce the risk of complications, particularly middle-ear barotrauma and oxygen toxicity. Studies using 1.2–1.5 ATA report barotrauma rates as low as 2–5.5%, compared with 33–43% in some higher-pressure protocols.
Accessibility. Mild chambers operating at 1.3–1.5 ATA can use soft-shell portable designs, dramatically reducing cost and increasing availability. These systems can be deployed in outpatient settings, homes, and community facilities where traditional hard-chamber systems are often financially out of reach.
Efficacy through frequency. Rather than requiring higher pressures, many conditions may respond just as well to more sessions at lower, safer pressures. The 2024 review found a near-linear relationship between total oxygen dose and symptom improvement — suggesting cumulative exposure matters as much as pressure intensity.
The traditional high-pressure perspective
In fairness, critics of mild hyperbaric therapy note that established protocols for conditions on the Undersea and Hyperbaric Medical Society's approved list typically require 2.0–2.5 ATA. They argue that the historical definition of HBOT — at least 1.4 ATA with 100% oxygen — exists because lower pressures and concentrations haven't demonstrated efficacy for approved indications like carbon monoxide poisoning, diabetic foot ulcers, and radiation tissue injury.
That said, the FDA's reclassification of HBOT as two separate therapeutic components — increased barometric pressure and hyperoxia — has complicated the debate, acknowledging that both elements may contribute independently to treatment effects.
Why you'll see this dismissed online
If you search around, you'll find plenty of confident claims that "1.3 ATA doesn't do anything," or that mild hyperbaric therapy is a placebo. That claim usually traces back to the same root cause described above: 1.3 ATA was historically used as the placebo condition in clinical trials. So when a trial found "no difference between groups," it got reported as "1.3 ATA doesn't work" — rather than the more accurate "we couldn't tell these two active treatments apart."
The claim isn't dishonest, exactly. It's a study-design assumption that's been repeated so often it now reads as settled fact — even though the researchers who ran these trials have themselves pushed back on it in print. As they've pointed out, 1.3 ATA simply cannot be both an active treatment and an inert control at the same time.
The bottom line for patients
When a study reports "no significant difference" between groups using 1.3 ATA as its control, the result may actually show that both pressures work — not that neither does. At Pioneer Valley Hyperbaric, we use mild protocols around 1.3 ATA specifically because the evidence supports it as a genuinely active, safe, and accessible therapy — not a placebo.
What this means for you
This controversy has real, practical implications — for how trials are designed, how their results get reported, and ultimately for the cost and accessibility of treatment. It reflects deeper questions about standardization and evidence thresholds in hyperbaric medicine. If you'd like to talk through what pressure and protocol make sense for your specific situation, we're happy to walk through the science with you.
Let's Talk
You don't need a diagnosis in hand to reach out.
We're happy to walk through the science, the evidence, and what to expect. Tell us a little about your situation and we'll take it from there — no pressure, no obligation.